Cargando…
Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation
Dilated cardiomyopathy (DCM) is the major cause of heart failure and has a poor prognosis. The accumulating evidence points to an essential role of the inflammatory component in the process of DCM. Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are widely used to treat heart failure patients d...
Autores principales: | Hu, Jiaxin, Xu, Jiamin, Tan, Xi, Li, Dong, Yao, Dejiang, Xu, Biao, Lei, Yuhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244283/ https://www.ncbi.nlm.nih.gov/pubmed/36749400 http://dx.doi.org/10.1007/s00210-023-02409-5 |
Ejemplares similares
-
Colchicine Ameliorates Dilated Cardiomyopathy Via SIRT2‐Mediated Suppression of NLRP3 Inflammasome Activation
por: Sun, Xuan, et al.
Publicado: (2022) -
NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy
por: Zeng, Cheng, et al.
Publicado: (2020) -
Autophagy and Inflammasome Activation in Dilated Cardiomyopathy
por: Caragnano, Angela, et al.
Publicado: (2019) -
Research progress on the activation mechanism of NLRP3 inflammasome in septic cardiomyopathy
por: Wen, Yuqi, et al.
Publicado: (2023) -
Research Progress of Mitochondrial Mechanism in NLRP3 Inflammasome Activation and Exercise Regulation of NLRP3 Inflammasome
por: Zhang, Tan, et al.
Publicado: (2021)